CHARACTERIZATION OF HUMAN PROSTATE-CANCER, BENIGN PROSTATIC HYPERPLASIA AND NORMAL PROSTATE BY IN-VITRO H-1 AND P-31 MAGNETIC-RESONANCE SPECTROSCOPY

被引：77

作者：

CORNEL, EB

SMITS, GAHJ

OOSTERHOF, GON

KARTHAUS, HFM

DEBRUYNE, FMJ

SCHALKEN, JA

HEERSCHAP, A

机构：

[1] UNIV HOSP NIJMEGEN, DEPT UROL, GEERT GROOTEPLE, N ZUID 16, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS

[2] UNIV HOSP NIJMEGEN, DEPT RADIOL, NIJMEGEN, NETHERLANDS

[3] CANISIUS WILHELMINA HOSP, DEPT UROL, NIJMEGEN, NETHERLANDS

来源：

JOURNAL OF UROLOGY | 1993年 / 150卷 / 06期

关键词：

METABOLISM; NUCLEAR MAGNETIC RESONANCE; PROSTATIC NEOPLASMS; PROSTATE; PROSTATIC HYPERTROPHY;

D O I：

10.1016/S0022-5347(17)35957-8

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

In vitro H-1 and P-31 magnetic resonance spectra were acquired from perchloric acid extracts of human prostate tissue obtained by transurethral resection. This included tissue of patients with benign prostatic hyperplasia and prostatic adenocarcinoma; one tissue sample was obtained from a patient without any sign of BPH or malignancy. Major resonances in the magnetic resonance spectra were assigned to prostate compounds and were quantified. The citrate/lactate, citrate/total choline, phosphocholine/total creatinine, choline/total creatine, alanine/total creatine, phosphoethanolamine/total phosphate, phosphocholine/total phosphate and glycerophosphoethanolamine/total phosphate ratios were statistically different for the prostate cancer samples as compared with the BPH specimens. These observations may contribute to the understanding of in vivo magnetic resonance spectra of the prostate and indicate that magnetic resonance spectroscopy can aid in the diagnosis of prostate malignancy.

引用

页码：2019 / 2024

页数：6

共 32 条

[1] Boring C.C., Squires T.S., Tong T., Cancer statistics 1992, Ca.: Cancer J. Clin., 42, (1992)
[2] Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen E., Yaun J.J.J., Petros J.A., Andriole G.L., Measurement of prostate specific antigen in serum as a screening test for prostate cancer, N. Engl. J. Med., 324, (1991)
[3] Ling D., Lee J.K.T., Heiken J.P., Balfe D.M., Glazer H.S., McClennan B.L., Prostatic carcinoma and benign prostatic hyperplasia: inability of MR imaging to distinguish between the two diseases, Radiology, 158, (1986)
[4] Rifkin M.D., Zerhouni E.A., Gatsonis C.A., Quint L.E., Paushter D.M., Epstein J.I., Hamper U., Walsh P.C., McNeil B.J., Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer, N. Engl. J. Med., 323, (1990)
[5] Schnall M.D., Lenkinski R.E., Pollack H.M., Imai Y., Ressel H.Y., Prostate: MR imaging with a transrectal surface coil, Radiology, 172, (1989)
[6] Narayan P., Vigneron D.B., Jajodia P., Anderson C.M., Hedgcock M.W., Tanagho E.A., James T.L., Transrectal probe for 1H MRI and 31P MR spectroscopy of the prostate gland, Magn. Reson. Med., 11, (1989)
[7] Narayan P., Jajodia P., Kurhanewicz J., Thomas A., MacDonald J., Hubesch B., Hedgcock M., Anderson C.M., James T.L., Tanagho E.A., Weiner M., Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31P magnetic resonance spectroscopy: a preliminary report, J. Urol., 146, (1991)
[8] Fowler A.H., Pappas A.A., Holder J.C., Finkbeiner A.E., Dalrymple G.V., Mullins M.S., Sprigg J.R., Komoroski R.A., Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR, Magn. Reson. Med., 25, (1992)
[9] Yacoe M.E., Sommer G., Peehl D., In vitro proton spectroscopy of normal and abnormal prostate, Magn. Reson. Med., 19, (1991)
[10] Schiebler M.L., Miyamoto K.K., White M., Maygarden S.L., Mohler J.L., In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma, Magn. Reson. Med., 29, (1993)

← 1 2 3 4 →